3-Month Trial Observation of A1c Change

This study has been terminated.
(Preliminary exploration of research concept did not prove to be viable.)
Information provided by (Responsible Party):
Dr. Hugh Tildesley, Endocrine Research Society
ClinicalTrials.gov Identifier:
First received: August 10, 2011
Last updated: August 10, 2015
Last verified: August 2015
The incidence of type 2 diabetes in long term care facilities has been approximated at 25% with barriers to treatment including untimely access to a specialist and improper/poor adherence to insulin regimes. This 3 month trial will investigate the efficacy of improving overall glycemic control by using an internet blood glucose reporting system to facilitate bi-weekly consultations between long term care facility patients with type 2 diabetes and an endocrinologist.

Condition Intervention
Type 2 Diabetes
Other: Internet Communication

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Official Title: Assessment of an Internet Blood Glucose Management Program in a Chronic Care Hospital

Resource links provided by NLM:

Further study details as provided by Endocrine Research Society:

Primary Outcome Measures:
  • HbA1c [ Time Frame: 0 and 3 months ] [ Designated as safety issue: No ]
    Hemoglobin A1c will be measure at 0 and 3 months to determine the efficacy of the internet blood glucose monitoring system as measured by change in glycemic control.

Secondary Outcome Measures:
  • Staff satisfaction [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Measure of hospital staff satisfaction of using the Health-e-Connect platform to help patients communicate with an endocrinologist

  • Frequency of Self-Monitoring [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Measure the frequency of blood glucose self-monitoring of the patients by collecting the total number of tests using the provided meter.

  • unplanned hospitalizations [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
    A secondary endpoint includes adverse events such as unplanned hospitalizations for any cause that last more than 24 hours

Enrollment: 10
Study Start Date: October 2011
Study Completion Date: September 2012
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Internet Intervention Other: Internet Communication
bi-weekly communication of blood sugars using an internet platform between patients with type 2 diabetes and an endocrinologist

Detailed Description:

Purpose: This project will investigate the benefits (as measured by change in the primary outcome measure hemoglobin A1c) of bi-weekly reporting of blood sugar values for patients with type 2 diabetes in long term care facilities.

Hypothesis: Our hypothesis is bi-weekly reporting will result in a reduction in A1c after 3 months.

Justification: Elevated A1c values increase risk of health complications for people with type 2 diabetes.

Objectives: Improved type 2 diabetes management for patients in long term care facilities.

Research Methods: Patients who meet the inclusion / exclusion criteria and are interested in participating in the study will self-identify to the research coordinator. Consent will be done in person with any questions answered. Strips and blood glucose meters will be provided. Blood glucose values and testing frequency will be recorded using the internet reporting system Heath-e-Connect. HbA1c, serum creatinine and demographic data will be collected at 0 and 3 months to determine effect of bi-weekly remote communication of blood glucose with an endocrinologist.

Statistical Analysis: HbAlc values at 0 and 3 months will be compared using an unpaired t-test to measure the effect of the intervention


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type II diabetes mellitus patients at Point Grey Private Hospital
  • Trained in self-blood glucose monitoring
  • Willingness to test blood glucose levels a minimum of 3 times daily
  • Willingness to be trained on IBGMS

Exclusion Criteria:

  • Patients with medical conditions that may affect their study participation or results will be excluded.
  • Patients currently being treated with steroid medication
  • Patients that have impaired liver function
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01415271

Canada, British Columbia
Endocrine Research Society
Vancouver, British Columbia, Canada, V6E 1M7
Sponsors and Collaborators
Endocrine Research Society
Principal Investigator: Hugh Tildesley Providence Health Care, University of British Columbia
  More Information

Responsible Party: Dr. Hugh Tildesley, Director, Endocrine Research Society
ClinicalTrials.gov Identifier: NCT01415271     History of Changes
Other Study ID Numbers: Point Grey Trial 
Study First Received: August 10, 2011
Last Updated: August 10, 2015
Health Authority: Canada: Canadian Institutes of Health Research

Keywords provided by Endocrine Research Society:
long term care

ClinicalTrials.gov processed this record on May 26, 2016